Real‐world outcomes using PD ‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
Katharina Schumann, Cornelia Mauch, Kai‐Christian Klespe, Carmen Loquai et autres
BACKGROUND: Programmed death-1 (PD-1) antibodies and BRAF + MEK inhibitors are widely used for adjuvant therapy of fully resected high-risk melanoma. Little is known about treatment efficacy outside of phase III trials. This real-world study reports on clinical outcomes of modern adjuvant …
de, at, ch (code pays fourni par la source)
31 citations
Journal of the European Academy of Dermatology and Venereology